Additionally, inhibiting antioxidant defenses by targeting pathways such as Nrf2 or STAT3 could reduce the antioxidant capacity of CLL cells, rendering them more susceptible to oxidative damage. This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.